Clinical trials: NERVES
Medulloblastoma, Childhood
Medulloblastoma Online Video-based Exercise Pilot Study
In this study, the investigators test whether it is possible to deliver an exercise intervention via video meetings to children and adolescents who have completed therapy for medulloblastoma.
- Trial name
- MOVE (NCT06898684)
- Testing
- Exercise
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 15 people
- Sponsor
- Aron Onerup
Carcinoid Tumor, Second Primary Malignant Neoplasm
The Risk of Second Primary Gastrointestinal Malignancies Following Primary Gastrointestinal Carcinoid Tumors: a SEER Based Study 2000-2022
Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course. Carcinoid tumors are the most common gastrointestinal (GI) neuroendocrine tumors.
- Trial name
- NCT07291752
- Volunteers
- 93,481 people
- Sponsor
- Suez Canal University
Neuroblastoma, Medulloblastoma
Molecular-Guided Therapy for Childhood Cancer
The purpose of this study is to test the feasibility (ability to be done) of experimental technologies to determine a tumor's molecular makeup.
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma
- Trial name
- NCT02162732
- Testing
- Guided Therapy
- Where
- 19 sites in United States, Lebanon
- Volunteers
- 186 people
- Sponsor
- Giselle Sholler
Tonsillitis
Suprazygomatic Maxillary Nerve Block in Pediatric Tonsillectomy
Tonsillectomies are among the most common surgical procedures performed in pediatric populations, with more than 14,000 procedures performed annually in Ontario, with more than 80% being performed to treat sleep-disordered…
- Trial name
- NCT07176533
- Testing
- Suprazygomatic maxillary nerve block (SZMN) with bupivacaine
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Brain Tumor, Recurrent, Brain Tumor
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
- Conditions
- Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic
- Trial name
- NCT04427384
- Testing
- GammaTile
- Where
- 54 sites in United States
- Volunteers
- 600 people
- Sponsor
- GT Medical Technologies, Inc.
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Implant Site Reaction
Neurosensory Disturbances After Inferior Alveolar Nerve Lateralization
Evaluation of the neurosensory disturbances after inferior alveolar nerve lateralization with and without isolation of the simultaneously placed implants using collagen membrane And measuring the stability of implants after…
- Trial name
- NCT03664219
- Testing
- isolation of IAN from implant with collagen membrane
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Cairo University
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin to see how well they work compared to cyclophosphamide and prednisone alone in treating patients with abnormal trunk muscle movements…
- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma
- Trial name
- NCT00033293
- Testing
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- 104 sites in United States, Australia and 1 more
- Volunteers
- 53 people
- Sponsor
- Children's Oncology Group
Humeral Fractures
Management of Displaced Supracondylar Fractures of the Humerus Using Lateral vs. Crossed K-wires
Completely displaced (Type III) supracondylar fractures of the humerus are treated in the operating room and are held together with pins stuck into the bone. There are two ways of inserting the pins: crossed and laterally.
- Trial name
- NCT00358787
- Testing
- Crossed K-wiring of supracondylar fracture of the humerus, Lateral K-wiring of supracondylar fracture of the humerus
- Where
- Canada
- Volunteers
- 55 people
- Sponsor
- University of British Columbia
Neuroblastoma
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
This is a phase II single center study to administer two courses of myeloablative consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC) rescue in patients with high-risk neuroblastoma who…
- Trial name
- NCT02605421
- Testing
- Thiotepa, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hand Injuries
Cross-cultural Adaptation of the 'Cold Intolerance Severity Score' (CISS) to the Dutch Language.
To report Cold intolerance by the CISS score in medicolegal patients.
- Trial name
- Ciss-DLV (NCT05925907)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given.
- Trial name
- NCT04655404
- Testing
- Larotrectinib, Larotrectinib surgical
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 15 people
- Sponsor
- Nationwide Children's Hospital
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)
Hypospadias
Liposomal Bupivacaine vs Standard Penile Block for Hypospadias Repair
The investigator proposes a prospective randomized study of males with hypospadias to either bupivacaine penile block or liposomal bupivacaine block for hypospadias repair, Figure 3.
- Trial name
- NCT04479371
- Testing
- Liposomal bupivacaine, Bupivacaine
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Glioma, Glioblastoma
Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
Background Currently, no standard treatment exists for patients with recurrent glioblastoma multiforme (rGBM) and used 2nd line treatments have low (up to max. 20%) response rates and very modest response duration (months).
- Trial name
- HUTMZ (NCT03463733)
- Testing
- Hydroxyurea, Temozolomide
- Where
- Netherlands
- Volunteers
- 54 people
- Sponsor
- M.E. van Linde
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002752
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Femoral Neuropathy
Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction: Femoral Nerve Block vs Patient-controlled Analgesia (PCA)
Femoral neuropathy after anterior cruciate ligament reconstruction with femoral nerve block may be as high as 24% at 6 postoperative weeks when evaluated prospectively and systematically through a clinical neurological and an…
- Trial name
- NCT01321138
- Testing
- Femoral nerve block, PCA morphine
- Where
- Switzerland
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
CNS Cancer, Neuroblastoma
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9
The purpose of this study is to find out whether the monoclonal antibody 8H9 is useful in finding tumors in your body. Antibodies are protein found naturally in blood. They can fasten themselves to bacteria and viruses.
- Conditions
- CNS Cancer, Neuroblastoma, Sarcoma
- Trial name
- NCT00582608
- Testing
- 131I-8H9, 8H9
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cauda Equina Syndrome, Functional Neurological Disorder
BLB Study Back or Leg Pain and Bladder Symptoms Study
The research focuses on Cauda Equina Syndrome (CES) which describes damage to the nerves in the lower back which supply bladder, bowels, sexual function and the legs usually from slipped discs in the spine.
- Trial name
- BLB (NCT03325374)
- Testing
- Questionnaires and examination
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Edinburgh
Diffuse Intrinsic Pontine Glioma
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
Diffuse Intrinsic Pontine Gliomas (DIPG) appear almost exclusively in children and adolescents, representing 15 to 20% of posterior fossa tumours.
- Trial name
- BIOMEDE (NCT02233049)
- Testing
- Erlotinib, Everolimus, Dasatinib
- Where
- France
- Volunteers
- 250 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.